Adaptive trial designs can facilitate the testing of agents that restore or bypass these pathways, such as epigenetic therapies that enhance antigen presentation or T cell activation, thereby improving outcomes in JAK1/2-mutant tumours [139,181]. Here, JAK1 is linked to neoplasm.